The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Updates in the DLBCL treatment landscape
John Burke, MD, Rocky Mountain Cancer Centers, US Oncology Research, Aurora, CO, discusses developments in the field of diffuse large B-cell lymphoma (DLBCL) treatment. Whilst R-CHOP and autologous stem cell transplants are the standard first-line and second-line treatments for DLBCL respectively, novel therapies have demonstrated superior efficacy. Polatuzumab vedotin, an antibody-drug conjugate, and R-CHP have shown to be a promising first-line treatment regimen in the Phase III POLARIX trial (NCT03274492), and ongoing trials have demonstrated the potential of chimeric antigen receptor (CAR) T-cell therapies to replace autologous stem cell transplantation. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
